FA ALPHA

FA Alpha Daily

Pfizer just made its biggest acquisition in years… let’s understand exactly why

Rather than setting their start-up research and development in motion, big pharma firms have a propensity to acquire companies’ technologies at a more mature stage. Today’s FA Alpha Daily will analyze if Pfizer’s (PFE) latest big-ticket acquisition, Biohaven, is worth the price.

FA Alpha Daily:
Thursday Uniform accounting analysis
Powered by Valens Research

Large pharmaceutical companies have long opposed legislation being considered by Congress to lower the prices of prescription drugs.

Their argument against such legislation has been based on the contention that reducing their revenues would reduce their investment in drug development and consequently discovering new medicines and treatments.

Congress has thus far resisted implementing such legislation, but it might be time to call into question why exactly drugs are so expensive.

One reason is because Pfizer (PFE) and the other big pharmaceutical companies aren’t good at start-up R&D. Instead, they let others do the hard work, and then acquire the technology for a premium when it is at a more mature stage.

The data backs up this claim as well.

An analysis of Pfizer in 2019 showed that they did not invent most of the drugs in their portfolio.

In fact, when we go back a few years, only 10 of Pfizer’s top 44 products in 2017 had the discovery and early research occur in-house. The other 70%+ of their portfolio was instead acquired from other companies.

With these acquired technologies accounting for 86% of their revenues, their claim that lowered prices would hamper in-house innovation starts making less sense.

As evidenced by its tremendous profitability over the years, it’s clear that Pfizer has done a good job of acquiring the right companies.

Thanks to over $32 billion in cash after its success with COVID-19 treatments and a series of patent cliffs in the portfolio nearing, Pfizer has been on the lookout for its next ticket to strong profitability.

This is why Pfizer just made a move on Biohaven for $11.6 billion, to acquire its blockbuster Remegepant drug.

While it appears that Pfizer paid a massive premium to the tune of a 79% premium over the closing price for the company, let’s use our Embedded Expectations Analysis to see if it’s a smart investment for Pfizer at the price it is paying and if it makes sense.

While we can see that Biohaven’s profitability has historically been strongly negative, analysts are predicting strong improvement as its drug moves to market.

If analyst expectations of 33% Uniform ROA in 2023 holds, embedded expectations of 29% at the $11.6 sale price makes it appear that Pfizer paid a reasonable rate for the company.

With Biohaven’s approved Remegepant, a potential migraine treatment blockbuster in the pipeline, Pfizer is on track to remain a massively profitable company by using its flush balance sheet on the right investments.

Investors relying on GAAP metrics to make financial decisions like this are constantly missing out on the true performance of companies across the market, making theme-based investing impossible. To learn more about how to gain access to the real numbers for almost 25,000 companies around the world, click here to read about our Uniform Accounting database.

SUMMARY and Pfizer Inc. Tearsheet

As the Uniform Accounting tearsheet for Pfizer Inc. (PFE:USA) highlights, the Uniform P/E trades at 6.7x, which is below the global corporate average of 20.6x as well as its own historical P/E of 10.3x.

Low P/Es require low EPS growth to sustain them. In the case of Pfizer, the company has recently shown a 149% Uniform EPS growth.

Wall Street analysts provide stock and valuation recommendations that in general provide very poor guidance or insight. However, Wall Street analysts’ near-term earnings forecasts tend to have relevant information.

We take Wall Street forecasts for GAAP earnings and convert them to Uniform earnings forecasts. When we do this, Pfizer’s Wall Street analyst-driven forecast is a 53% growth and a 35% EPS decline in 2022 and 2023, respectively.

Based on the current stock market valuations, we can use earnings growth valuation metrics to back into the required growth rate to justify Pfizer’s $54 stock price. These are often referred to as market embedded expectations.

The company is currently being valued as if Uniform earnings were to shrink by 15% annually over the next three years. What Wall Street analysts expect for Pfizer’s earnings growth is above what the current stock market valuation requires in 2022, but is below that requirement in 2023.

Furthermore, the company’s earning power in 2021 is 5x the long-run corporate average. Also, cash flows and cash on hand are over 3x its total obligations—including debt maturities, capex maintenance, and dividends. Overall, this signals low credit and dividend risk.

Lastly, Pfizer’s Uniform earnings growth is above its peer averages, but the company is trading below its average peer valuations.

Best regards,

Joel Litman & Rob Spivey

Chief Investment Strategist &
Director of Research
at Valens Research

 

The Uniform Accounting insights in today’s issue are the same ones that power some of our best stock picks and macro research, which can be found in our FA Alpha Daily newsletters.

Subscriptions & Services

Interested in getting unique Uniform Accounting insights right to your inbox every day?

No credit card required, our FA Alpha Daily newsletter is free of charge.
And loaded with things you won’t hear anywhere else.

You don’t have access to the Valens Research Premium Application.

To get access to our best content including the highly regarded Conviction Long List and Market Phase Cycle macro newsletter, please contact our Client Relations Team at 630-841-0683 or email client.relations@valens-research.com.

Please fill out the fields below so that our client relations team can contact you

Or contact our Client Relationship Team at 630-841-0683